Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 28.02 Million SEK | -0.96% |
| 2022 | 28.3 Million SEK | 43.02% |
| 2021 | 19.78 Million SEK | -18.54% |
| 2020 | 24.28 Million SEK | 7.17% |
| 2019 | 22.66 Million SEK | 14.74% |
| 2018 | 19.75 Million SEK | 29.1% |
| 2017 | 15.3 Million SEK | -22.07% |
| 2016 | 19.63 Million SEK | -5.64% |
| 2015 | 20.8 Million SEK | -9.25% |
| 2014 | 22.92 Million SEK | 20.78% |
| 2013 | 18.98 Million SEK | -6.58% |
| 2012 | 20.32 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 27.18 Million SEK | 7.4% |
| 2024 Q1 | 28.64 Million SEK | 2.22% |
| 2024 Q2 | 25.31 Million SEK | -11.65% |
| 2023 Q3 | 33.5 Million SEK | 12.86% |
| 2023 FY | 28.02 Million SEK | -0.96% |
| 2023 Q2 | 29.68 Million SEK | -0.52% |
| 2023 Q1 | 29.84 Million SEK | 5.44% |
| 2023 Q4 | 28.02 Million SEK | -16.34% |
| 2022 Q4 | 28.3 Million SEK | 9.61% |
| 2022 Q3 | 25.81 Million SEK | 15.09% |
| 2022 FY | 28.3 Million SEK | 43.02% |
| 2022 Q1 | 20.25 Million SEK | 2.34% |
| 2022 Q2 | 22.43 Million SEK | 10.78% |
| 2021 Q4 | 19.78 Million SEK | -11.81% |
| 2021 Q1 | 24.2 Million SEK | -0.35% |
| 2021 Q2 | 24.53 Million SEK | 1.36% |
| 2021 Q3 | 22.43 Million SEK | -8.54% |
| 2021 FY | 19.78 Million SEK | -18.54% |
| 2020 FY | 24.28 Million SEK | 7.17% |
| 2020 Q4 | 24.28 Million SEK | 4.53% |
| 2020 Q3 | 23.23 Million SEK | 9.39% |
| 2020 Q1 | 23.4 Million SEK | 3.27% |
| 2020 Q2 | 21.24 Million SEK | -9.25% |
| 2019 Q4 | 22.66 Million SEK | -0.2% |
| 2019 Q1 | 22.36 Million SEK | 13.24% |
| 2019 FY | 22.66 Million SEK | 14.74% |
| 2019 Q3 | 22.71 Million SEK | 10.78% |
| 2019 Q2 | 20.5 Million SEK | -8.35% |
| 2018 Q2 | 16.06 Million SEK | -13.92% |
| 2018 Q3 | 18.81 Million SEK | 17.09% |
| 2018 Q4 | 19.75 Million SEK | 5.01% |
| 2018 FY | 19.75 Million SEK | 29.1% |
| 2018 Q1 | 18.66 Million SEK | 21.98% |
| 2017 Q4 | 15.3 Million SEK | 13.8% |
| 2017 FY | 15.3 Million SEK | -22.07% |
| 2017 Q3 | 13.44 Million SEK | -5.99% |
| 2017 Q2 | 14.3 Million SEK | -14.4% |
| 2017 Q1 | 16.7 Million SEK | -14.9% |
| 2016 Q2 | 22.74 Million SEK | -6.55% |
| 2016 Q4 | 19.63 Million SEK | -16.18% |
| 2016 FY | 19.63 Million SEK | -5.64% |
| 2016 Q1 | 24.34 Million SEK | 16.99% |
| 2016 Q3 | 23.42 Million SEK | 2.96% |
| 2015 Q1 | 28.23 Million SEK | 23.16% |
| 2015 FY | 20.8 Million SEK | -9.25% |
| 2015 Q4 | 20.8 Million SEK | -9.14% |
| 2015 Q3 | 22.9 Million SEK | -0.38% |
| 2015 Q2 | 22.98 Million SEK | -18.6% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | 27.67 Million SEK | 0.0% |
| 2014 Q4 | 22.92 Million SEK | -17.15% |
| 2014 FY | 22.92 Million SEK | 20.78% |
| 2013 Q4 | 18.98 Million SEK | 0.0% |
| 2013 FY | 18.98 Million SEK | -6.58% |
| 2012 FY | 20.32 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -309.811% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 76.875% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 76.875% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 5.461% |
| BICO Group AB (publ) | 493.1 Million SEK | 94.316% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 55.085% |
| CellaVision AB (publ) | 126.03 Million SEK | 77.763% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -358.332% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -1482.623% |
| C-Rad AB (publ) | 64.09 Million SEK | 56.276% |
| Duearity AB (publ) | 4.15 Million SEK | -573.888% |
| Dignitana AB (publ) | 7.41 Million SEK | -278.079% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -657.486% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.563% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 1764.933% |
| Iconovo AB (publ) | -4.86 Million SEK | 676.45% |
| Integrum AB (publ) | 22.36 Million SEK | -25.333% |
| Luxbright AB (publ) | 8000.00 SEK | -350237.5% |
| Mentice AB (publ) | 14.1 Million SEK | -98.717% |
| OssDsign AB (publ) | 4.3 Million SEK | -551.185% |
| Paxman AB (publ) | 19.99 Million SEK | -40.142% |
| Promimic AB (publ) | 330 Thousand SEK | -8393.03% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -284.353% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -135.146% |
| ScandiDos AB (publ) | 22.69 Million SEK | -23.521% |
| Sectra AB (publ) | 36.59 Million SEK | 23.403% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 34.783% |
| Senzime AB (publ) | 20.34 Million SEK | -37.793% |
| SpectraCure AB (publ) | 1.00 SEK | -2802699900.0% |
| Stille AB | 66.55 Million SEK | 57.888% |
| Vitrolife AB (publ) | 413 Million SEK | 93.214% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 80.207% |